HCM
ACHV icon

Highbridge Capital Management’s Achieve Life Sciences ACHV Stock Holding History

Highbridge Capital Management’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-132,937
Closed -$300K – 308
2025
Q2 		$300K Buy
+132,937
New +$379K 0.01% 135
2013
Q3 		– Sell
-8
Closed -$181K – 1240
2013
Q2 		$181K Buy
+8
New +$179K ﹤0.01% 1195

Other funds holding ACHV

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Highbridge Capital Management's ACHV Position: Q3 2025 in Review

Highbridge Capital Management sold out of Achieve Life Sciences (ACHV) in Q3 2025, closing a stake of 132,937 shares — an estimated $300K sold.

Highbridge Capital Management first reported a position in ACHV in Q2 2013 and held it in 2 quarters. The position peaked at $300K in Q2 2025. 66 funds tracked by Wall St. Rank hold ACHV as of Q3 2025.

  • Highbridge Capital Management reported no remaining Achieve Life Sciences position as of Q3 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 132,937 Achieve Life Sciences shares in Q3 2025, an estimated $300K.
  • Highbridge Capital Management first reported a position in Achieve Life Sciences in Q2 2013 and held it in 2 quarters.
  • Highbridge Capital Management's Achieve Life Sciences position peaked at $300K in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2025.

Based on Highbridge Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.